Literature DB >> 17982656

Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition.

Min Young Park1, Kyung Ryoul Kim, Ho Sung Park, Byung-Hyun Park, Ha Na Choi, Kyu Yun Jang, Myoung Ja Chung, Myoung Jae Kang, Dong Geun Lee, Woo Sung Moon.   

Abstract

The acquisition of a migratory and invasive phenotype by cells of epithelial origin is associated with a gain of mesenchymal characteristics concomitant with a loss of the epithelial phenotype, a phenomenon referred to as epithelial-mesenchymal transition (EMT). Vimentin, a cytoplasmic intermediate filament, is characteristic of mesenchymal cells and is usually not expressed in epithelial cells. Increased expression of vimentin in carcinomas correlates with parameters of malignant potential such as tumor grade and tumor invasion. Serum response factor (SRF) regulates transcription of immediate early genes and triggers proliferation, migration and differentiation in several types of cells. However, the role of SRF in hepatocellular carcinoma (HCC) has not been explored. The aims of this study were to evaluate the expression of SRF and to assess a functional role of SRF in HCC. First, we examined the expression of SRF in 55 human specimens of HCC and four different HCC cell lines, including a sarcomatoid HCC cell line. We also examined the role of SRF in HCC by transfection of an SRF expression plasmid into a HCC cell line. SRF was expressed in 13 of 55 cases of HCC. SRF was predominantly expressed in HCC cells, with intense labeling in the nucleus. No staining was observed in hepatocytes of normal and cirrhotic liver outside the tumor. SRF was significantly up-regulated in high grade HCC, especially in sarcomatoid HCC. Overexpression of SRF in hepatocellular carcinoma cells accelerates migration and invasion with subsequent acquisition of mesenchymal phenotype by expression of a mesenchymal marker (vimentin) and activation of immediate early genes. We propose for the first time that the expression of SRF in HCC cells associated with EMT may play an important role in HCC progression. Thus, functional antagonism of SRF will provide an additional therapeutic approach by controlling tumor cell invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982656

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  26 in total

1.  A pathogenic relationship between a regulator of the actin cytoskeleton and serum response factor.

Authors:  Angela M Verdoni; Keaton J Schuster; Brian S Cole; Akihiro Ikeda; Winston W Kao; Sakae Ikeda
Journal:  Genetics       Date:  2010-07-06       Impact factor: 4.562

2.  The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma.

Authors:  C Hermanns; V Hampl; K Holzer; A Aigner; J Penkava; N Frank; D E Martin; K C Maier; N Waldburger; S Roessler; M Goppelt-Struebe; I Akrap; A Thavamani; S Singer; A Nordheim; T Gudermann; S Muehlich
Journal:  Oncogene       Date:  2017-01-23       Impact factor: 9.867

Review 3.  MDM2-p53 pathway in hepatocellular carcinoma.

Authors:  Xuan Meng; Derek A Franklin; Jiahong Dong; Yanping Zhang
Journal:  Cancer Res       Date:  2014-12-04       Impact factor: 12.701

4.  Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.

Authors:  Cho-Rok Jung; Jung Hwa Lim; Yoonjung Choi; Dae-Ghon Kim; Koo Jeong Kang; Seung-Moo Noh; Dong-Soo Im
Journal:  J Clin Invest       Date:  2010-11-08       Impact factor: 14.808

5.  Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma.

Authors:  Cheng-Hao Wang; Xiao-Dong Zhu; De-Ning Ma; Hui-Chuan Sun; Dong-Mei Gao; Ning Zhang; Cheng-Dong Qin; Yuan-Yuan Zhang; Bo-Gen Ye; Hao Cai; Wen-Kai Shi; Man-Qin Cao; Zhao-You Tang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

6.  Serum response factor: positive and negative regulation of an epithelial gene expression network in the destrin mutant cornea.

Authors:  Sharolyn V Kawakami-Schulz; Angela M Verdoni; Shannon G Sattler; Erik Jessen; Winston W-Y Kao; Akihiro Ikeda; Sakae Ikeda
Journal:  Physiol Genomics       Date:  2014-02-18       Impact factor: 3.107

7.  Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment?

Authors:  Olga Genin; Gideon Rechavi; Arnon Nagler; Ofer Ben-Itzhak; Kellie J Nazemi; Mark Pines
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

8.  Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.

Authors:  Alissa R Verone; Kelly Duncan; Alejandro Godoy; Neelu Yadav; Andrei Bakin; Shahriar Koochekpour; Jian-Ping Jin; Hannelore V Heemers
Journal:  Carcinogenesis       Date:  2013-04-10       Impact factor: 4.944

9.  MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.

Authors:  Shoumei Bai; Mohd W Nasser; Bo Wang; Shu-Hao Hsu; Jharna Datta; Huban Kutay; Arti Yadav; Gerard Nuovo; Pawan Kumar; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

Review 10.  Glioma pathogenesis-related protein 1 performs dual functions in tumor cells.

Authors:  Junjie Wang; Zeyu Li; Fenfen Yin; Rui Zhang; Ying Zhang; Zhengxin Wang; Xiumei Sheng
Journal:  Cancer Gene Ther       Date:  2021-03-19       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.